This Article Full Text Full Text (PDF) All Versions of this Article: 114/22/2317    most recent CIRCULATIONAHA.106.628537v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sacher, F. Articles by Le Marec, H. Search for Related Content PubMed PubMed Citation Articles by Sacher, F. Articles by Le Marec, H. Pubmed/NCBI databases Medline Plus Health Information Pacemakers and Implantable Defibrillators Related Collections Ablation/ICD/surgery Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2006;114:2317-2324.)
© 2006 American Heart Association, Inc.

Arrhythmia/Electrophysiology

Outcome After Implantation of a Cardioverter-Defibrillator in Patients With Brugada Syndrome

A Multicenter Study

Frédéric Sacher, MD; Vincent Probst, MD, PhD; Yoshito Iesaka, MD; Peggy Jacon, MD; Julien Laborderie, MD; Frédérique Mizon-Gérard, MD; Philippe Mabo, MD; Sylvain Reuter, MD; Dominique Lamaison, MD; Yoshihide Takahashi, MD; Mark D. O’Neill, MB, BCh, DPhil; Stéphane Garrigue, MD, PhD; Bertrand Pierre, MD; Pierre Jaïs, MD; Jean-Luc Pasquié, MD, PhD; Mélèze Hocini, MD; Michèle Salvador-Mazenq, MD; Akihiko Nogami, MD; Alain Amiel, MD; Pascal Defaye, MD; Pierre Bordachar, MD; Serge Boveda, MD; Philippe Maury, MD; Didier Klug, MD, PhD; Dominique Babuty, MD, PhD; Michel Haïssaguerre, MD; Jacques Mansourati, MD; Jacques Clémenty, MD; Hervé Le Marec, MD, PhD

From the Université Bordeaux II, Hôpital Cardiologique du Haut-Lévêque, Bordeaux-Pessac, France (F.S., M.D.O., P. Jais, M. Hocini, P.B., M. Haïssaguerre, J.C.); Institut du thorax, CHU de Nantes, France (V.P., H.L.M.); Tsuchiura Kyodo Hospital, Japan (Y.I., Y.T.); CHU de Grenoble, France (P. Jacon, P.D.); CHU de Poitiers, France (J.L., A.A.); CHU de Lille, France (F.M.-G., D.K.); CHU de Rennes, France (P. Mabo); Hopital Saint André, Bordeaux, France (S.R.); CHU de Clermont-Ferrand, France (D.L.); Clinique Saint Augustin, Bordeaux, France (S.G.); CHU de Tours, France (B.P., D.B.); CHU de Montpellier, France (J.-L.P.); CHU de Toulouse, France (M.S.-M., P. Maury); Yokohama Rosai Hospital, Japan (A.N.); Clinique Pasteur, Toulouse, France (S.B.); and CHU de Brest, France (J.M.).

Correspondence to Dr Frédéric Sacher, Hôpital Cardiologique du Haut-Lévêque, 33604 Bordeaux-Pessac, France. E-mail frederic.sacher{at}chu-bordeaux.fr

Received March 22, 2006; revision received September 26, 2006; accepted September 29, 2006

Background— Brugada syndrome is an arrhythmogenic disease characterized by an increased risk of sudden cardiac death (SCD) by ventricular fibrillation. At present, an implantable cardioverter-defibrillator (ICD) is the recommended therapy in high-risk patients. This multicenter study reports the outcome of a large series of patients implanted with an ICD for Brugada syndrome.

Methods and Results— All patients (n=220, 46±12 years, 183 male) with a type 1 Brugada ECG pattern implanted with an ICD in 14 centers between 1993 and 2005 were investigated. ICD indication was based on resuscitated SCD (18 patients, 8%), syncope (88 patients, 40%), or positive electrophysiological study in asymptomatic patients (99 patients, 45%). The remaining 15 patients received an ICD because of a family history of SCD or nonsustained ventricular arrhythmia. During a mean follow-up of 38±27 months, no patient died and 18 patients (8%) had appropriate device therapy (10±15 shocks/patient, 26±33 months after implantation). The complication rate was 28%, including inappropriate shocks, which occurred in 45 patients (20%, 4±3 shocks/patient, 21±20 months after implantation). The reasons for inappropriate therapy were lead failure (19 patients), T-wave oversensing (10 patients), sinus tachycardia (10 patients), and supraventricular tachycardia (9 patients). Among implantation parameters, high defibrillation threshold, high pacing threshold, and low R-wave amplitude occurred, respectively, in 12%, 27%, and 15% of cases.

Conclusion— In this large Brugada syndrome population, a low incidence of arrhythmic events was found, with an annual event rate of 2.6% during a follow-up of >3 years, in addition to a significant risk of device-related complications (8.9%/year). Inappropriate shocks were 2.5 times more frequent than appropriate ones.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				Developed in collaboration with, European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), and Heart Rhythm Society (HRS), Endorsed by the following societies, European Society of Emergency Medicine (EuSEM), European Federation of Internal Medicine (EFIM), European Union Geriatric Medicine Society (EUGMS), American Geriatrics Society (AGS), European Neurological Society (ENS), et al. Guidelines for the diagnosis and management of syncope (version 2009): The Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC) Eur. Heart J., November 1, 2009; 30(21): 2631 - 2671. [Full Text] [PDF]

				S. Kamakura, T. Ohe, K. Nakazawa, Y. Aizawa, A. Shimizu, M. Horie, S. Ogawa, K. Okumura, K. Tsuchihashi, K. Sugi, et al. Long-Term Prognosis of Probands With Brugada-Pattern ST-Elevation in Leads V1-V3 Circ Arrhythm Electrophysiol, October 1, 2009; 2(5): 495 - 503. [Abstract] [Full Text] [PDF]

				Task force members, J. Vijgen, G. Botto, J. Camm, C.-J. Hoijer, W. Jung, J.-Y. Le Heuzey, A. Lubinski, T. M. Norekval, M. Santomauro, et al. Consensus statement of the European Heart Rhythm Association: updated recommendations for driving by patients with implantable cardioverter defibrillators Europace, August 1, 2009; 11(8): 1097 - 1107. [Abstract] [Full Text] [PDF]

				G Lin, R A Nishimura, B J Gersh, D Phil, S R Ommen, M J Ackerman, and P A Brady Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy Heart, May 1, 2009; 95(9): 709 - 714. [Abstract] [Full Text] [PDF]

				N. P. Sidik, C. N. Quay, F. C. Loh, and L. Y. Chen Prevalence of Brugada sign and syndrome in patients presenting with arrhythmic symptoms at a Heart Rhythm Clinic in Singapore Europace, May 1, 2009; 11(5): 650 - 656. [Abstract] [Full Text] [PDF]

				Task Force members, M. Brignole, P. Vardas, E. Hoffman, H. Huikuri, A. Moya, R. Ricci, N. Sulke, W. Wieling, EHRA Scientific Documents Committee, et al. Indications for the use of diagnostic implantable and external ECG loop recorders Europace, May 1, 2009; 11(5): 671 - 687. [Full Text] [PDF]

				C. Giustetto, S. Drago, P. G. Demarchi, P. Dalmasso, F. Bianchi, A. S. Masi, P. Carvalho, E. Occhetta, G. Rossetti, R. Riccardi, et al. Risk stratification of the patients with Brugada type electrocardiogram: a community-based prospective study Europace, April 1, 2009; 11(4): 507 - 513. [Abstract] [Full Text] [PDF]

				F. Sacher, V. Probst, M. Bessouet, M. Wright, A. Maluski, S. Abbey, P. Bordachar, A. Deplagne, S. Ploux, G. Lande, et al. Remote implantable cardioverter defibrillator monitoring in a Brugada syndrome population Europace, April 1, 2009; 11(4): 489 - 494. [Abstract] [Full Text] [PDF]

				M. Brignole, J.-J. Blanc, R. Sutton, and A. Moya CHAPTER 26 Syncope ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]

				S. Peters Arrhythmogenic right ventricular dysplasia-cardiomyopathy and provocable coved-type ST-segment elevation in right precordial leads: clues from long-term follow-up Europace, July 1, 2008; 10(7): 816 - 820. [Abstract] [Full Text] [PDF]

				L. van Erven and M. J Schalij Troubleshooting implantable cardioverter-defibrillator related problems Heart, May 1, 2008; 94(5): 649 - 660. [Full Text] [PDF]

				J. Francis and C. Antzelevitch Atrial Fibrillation and Brugada Syndrome J. Am. Coll. Cardiol., March 25, 2008; 51(12): 1149 - 1153. [Abstract] [Full Text] [PDF]

				T. Rossenbacker, S. G. Priori, and D. P. Zipes The fight against sudden cardiac death: consensus guidelines as a reference Eur. Heart J. Suppl., December 1, 2007; 9(suppl_I): I50 - I58. [Abstract] [Full Text] [PDF]

				G. Boriani, R. Ricci, T. Toselli, R. Ferrari, A. Branzi, and M. Santini Implantable cardioverter defibrillators: from evidence of trials to clinical practice Eur. Heart J. Suppl., December 1, 2007; 9(suppl_I): I66 - I73. [Abstract] [Full Text] [PDF]

				A. Sarkozy, P. Brugada, L. Mont, and J. Brugada Optimizing the clinical use of implantable defibrillators in patients with Brugada syndrome Eur. Heart J. Suppl., December 1, 2007; 9(suppl_I): I74 - I80. [Abstract] [Full Text] [PDF]

				S. Viskin, C. Antzelevitch, M. F. Marquez, and B. Belhassen Quinidine: a valuable medication joins the list of 'endangered species' Europace, December 1, 2007; 9(12): 1105 - 1106. [Full Text] [PDF]

				S. Viskin and O. Rogowski Asymptomatic Brugada syndrome: a cardiac ticking time-bomb? Europace, September 1, 2007; 9(9): 707 - 710. [Full Text] [PDF]

				E. A. Stephenson and C. I. Berul Electrophysiological Interventions for Inherited Arrhythmia Syndromes Circulation, August 28, 2007; 116(9): 1062 - 1080. [Full Text] [PDF]

				S. Viskin Brugada Syndrome in Children: Don't Ask, Don't Tell? Circulation, April 17, 2007; 115(15): 1970 - 1972. [Full Text] [PDF]